# Teen Cannabis Use Linked to Spike in 'Scromiting' Cases
A new medical study documents a sharp rise in cases of cannabinoid hyperemesis syndrome, or CHS, among teenagers and young adults who use cannabis regularly. The condition, colloquially known as "scromiting" due to its combination of screaming and vomiting, presents severe abdominal pain alongside uncontrollable nausea and vomiting episodes.
Researchers have confirmed what medical professionals have long observed: chronic marijuana use triggers this syndrome in susceptible users. The condition emerges after extended periods of regular cannabis consumption and resolves only when users stop taking the drug entirely.
CHS manifests in three distinct phases. The prodromal phase begins with subtle nausea and mild stomach discomfort that worsens over weeks or months. Users often increase their cannabis intake during this stage, believing the drug will ease their symptoms. The hyperemetic phase follows, marked by severe vomiting that can last for hours and causes intense abdominal and chest pain. Some patients report taking scalding hot baths or showers, a behavior documented across multiple case studies, though the mechanism remains unclear. The recovery phase occurs after cannabis cessation, with symptoms gradually subsiding over days to weeks.
The spike in reported cases reflects both increased cannabis potency and higher rates of regular use among young people. Modern marijuana products contain significantly higher concentrations of tetrahydrocannabinol (THC) than cannabis available decades ago. Edibles, concentrates, and vaping products deliver THC more efficiently, creating conditions more favorable to CHS development.
Emergency departments across the United States report rising admissions for this condition. Young adults present with severe dehydration, electrolyte imbalances, and acute abdominal pain that initially mimics other serious conditions like appendicitis or bowel obstruction. Repeated hospitalizations and unnecessary surgeries have occurred before CHS diagnosis.
The medical community has worked to raise awareness among healthcare providers and the public. Recognition remains inconsistent. Many patients and physicians unfamiliar with CHS attribute symptoms to other gastrointestinal disorders, delaying proper diagnosis. Some users self-treat with increasingly higher cannabis doses, worsening their condition.
Public health officials face a messaging challenge. As cannabis legalization expands across states, counseling about CHS must reach recreational users who may not consider their consumption pattern risky. The condition primarily affects heavy, daily users rather than casual consumers, but prevalence estimates remain uncertain due to underdiagnosis and unreported cases.
Treatment remains straightforward but requires commitment. Complete cannabis cessation stops progression and allows recovery. No medication reliably controls CHS symptoms while cannabis use continues. Supportive care including intravenous fluids and anti-nausea medications provides temporary relief during acute episodes, but addresses only symptoms rather than the root cause.
Researchers recommend that public health campaigns accompanying cannabis legalization include information about CHS, particularly targeting young users. Medical schools and emergency medicine training programs should incorporate CHS education to improve diagnostic accuracy. As cannabis use becomes more normalized and products grow more potent, healthcare systems must prepare for continued increases in CHS cases without a corresponding rise in public awareness about the condition.